Author Correction: An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

Huiping Shuai(Chinese University of Hong Kong), Hin Chu(HKU-Pasteur Research Pole), Hoi Ting Wong(University of Hong Kong), Ziyi Xia(Sichuan University), Xiaoyan Xia(Guangzhou Women and Children Medical Center), Chaemin Yoon(University of Hong Kong), Yang Wang(First Affiliated Hospital of Guangzhou Medical University), Yue Chai(Chinese University of Hong Kong), Shuofeng Yuan(University of Hong Kong), Tianrenzheng Zhu(University of Hong Kong), Bingjie Hu(Wenzhou Medical University), Jiaheng Hu(University of Hong Kong), Yongtao Ye(Department of Health), Huan Liu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Baptist University), Minmin Zhou(University of Hong Kong), Yuxin Hou(University of Hong Kong), Shengyong Yang(Sichuan University), Jian Lei(Sichuan University), Yuanchen Liu(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Jialu Shi(University of Hong Kong), Chunfu Xu(National Institute of Biological Sciences, Beijing), Yuying Pan(First Affiliated Hospital of Guangzhou Medical University), Yifei Wang(Southwest Medical University), Dong Wang(Guangzhou Medical University), Lei Wang(Tang Hospital), Guo Zhang(Sichuan University), Honglei Zhang(University of Hong Kong), Yan Chen(PLA Army Service Academy), Qingquan Li(National Institute of Biological Sciences, Beijing), Jingxin Qiao(Sichuan University), Zhen Fang(Shanghai Customs College), Lianzhao Du(University of Hong Kong), Jie Zhou(Chinese University of Hong Kong), Jingyi Su(First Affiliated Hospital of Guangzhou Medical University), Xinyue Deng(Jilin University)
Nature Communications
December 15, 2025
Cited by 0


Related Papers